Merck & Co

News

BI to trial SIRP drug with in-house PD-1 inhibitor

Boehringer Ingelheim has revealed further details about its plans for a new kind of cancer immunotherapy licensed in from biotech OSE Therapeutics at the beginning of last month, saying it

News

KEYTRUDA is a prescription medicine used to treat a kind of skin cancer called melanoma

Keytruda 100mg/4mL Vial and Carton
2015

'Keytruda is King' in lung cancer, putting BMS and next-gen ...

Merck & Co is pressing home its precious advantage over rival Bristol-Myers Squibb in first line lung cancer, announcing new figures from its checkpoint inhibitor Keytruda that suggest the drug could revolutionise treatment when combined with chemotherapy.

News

Incyte shares down sharply after phase 3 skin cancer trial f...

Trial tested epacadostat pill in combination with Merck & Co’s Keytruda

News

Pfizer eyes gastro use for Xeljanz after thumbs-up from FDA ...

Pfizer has been steadily building a franchise around its inflammatory diseases pill, Xeljanz (tofacitinib) over the last few years, and it could add another use after US experts recommended

News

Merck shows canny cancer strategy in $5.76bn Eisai milestone...

Firms will co-develop Lenvima and Keytruda combinations

News

BMS seizes Opdivo dosing advantage over Keytruda

Bristol-Myers Squibb has scored a victory against arch-rivals Merck, with a new much more convenient dosing schedule for Opdivo which could help it keep ahead in the sales race.

BI to trial SIRP drug with in-house PD-1 inhibitor

'Keytruda is King' in lung cancer, putting BMS and next-gen ...

Incyte shares down sharply after phase 3 skin cancer trial f...

Pfizer eyes gastro use for Xeljanz after thumbs-up from FDA ...

Merck shows canny cancer strategy in $5.76bn Eisai milestone...

BMS seizes Opdivo dosing advantage over Keytruda

J&J claims FDA's latest national priority voucher

The AI imperative: Establishing the standard for modern clin...

Merck &amp; Co

Editor's Picks

Merck & Co